ClinicalTrials.gg
CompletedNCT05814926Updated Nov 15, 2023

GP681 in Volunteers With Hepatic Impairment Compared With Healthy Volunteers

A Phase 1 interventional study of GP681 in Healthy Volunteers and Hepatic Impairment, sponsored by Jiangxi Qingfeng Pharmaceutical Co. Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 68 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-11-15.

Sponsored by Jiangxi Qingfeng Pharmaceutical Co. Ltd. (part of Qingfeng Pharmaceutical Group Co., Ltd.) · Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Non-randomized
Ages
18 Years to 68 Years
Sex
All
01

Study summary

The primary objective of this study is to test whether mild (Child-Pugh A, score 5-6) and moderate (Child-Pugh B, score 7-9) hepatic impairment affects pharmacokinetics, safety and tolerability of GP681, compared with a control group with normal hepatic function following oral administration of GP681 as single dose.

Read the detailed description

This is a multicenter, open-label, parallel group, single-dose study to compare pharmacokinetics of GP681 after a single 40mg oral dose in eight healthy subjects and eight mild or eight moderate hepatic impairment subjects. Subjects with hepatic impairment will be enrolled into either mild (Child-Pugh A, score 5-6) or moderate (Child-Pugh B, score 7-9) hepatic impairment groups. The healthy subjects will match with impaired hepatic function patients on ethnic group, sex(+/- 1 subject), age (+/- 10 years) and weight (+/- 25%).

Participants will be admitted into the Clinical Research Units(CRU) on Day-1. On the morning of Day 1, subjects will receive a single 40 mg oral dose of GP681 following an overnight fast (i.e., at least 10 hours). Participants will be confined to the CRU until discharge on Day 12, with PK blood sample draws for measurement of GP681 and its main metabolites being taken throughout the confinement.

Safety assessments will include physical examinations, ECGs, vital signs, standard clinical laboratory evaluations (hematology, blood chemistry, urinalysis, coagulation), AE and serious adverse event (SAE) monitoring.

All participants will have a post-study safety follow-up contact conducted approximately 12 days after administration of study treatment. The study will be considered complete once all the participants have finished the required assessments, dropped out, or been lost to follow-up before completing the required assessments.

02

Conditions studied

  • Healthy Volunteers
  • Hepatic Impairment
03

In context

Lead sponsor

Jiangxi Qingfeng Pharmaceutical Co. Ltd. is the lead sponsor of 32 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 68 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female participants,between the ages of 18 and 68 years of age (inclusive) at the time of Screening;
  2. Body weight ≥50 kg for males, ≥45kg for females, and (BMI) between18-30 kg/m\^2(inclusive);
  3. Voluntarily sign the form, understand the trial procedures, and be willing to comply with all trial procedures and restrictions.

Participants with Hepatic Impairment Only:

Participants must satisfy the criteria for primary liver disease as evidenced by a A (score 5-6), B (score 7-9). Treatment-naïve participants for at least 4 weeks before screening can be entered into the study. Unless otherwise stated, participants must have been on stable doses and regimens of the concomitant medication for at least 4 weeks before screening.

Participants with Normal Hepatic Function Only:

  1. Healthy participants, between the ages of 18 and 68 years of age (inclusive) at the time of Screening, matched to participants with hepatic impairment with regard to age (+/-10 years), and gender(+/-1 subject);
  2. Body weight ≥50 kg for males, ≥45kg for females, and body mass index (BMI) between18-30 kg/m\^2(inclusive), matched to participants with hepatic impairment with regard to body weight (+/-25% kg);
  3. In good health, determined by no findings from vital signs, physical examination, 12-lead (ECG), clinical laboratory evaluations, and other safety examinations at screening, as assessed by the investigator.
  4. Men must agree to use protocol-specified and also to not donate sperm throughout the study and for at least 3 months after the final dose of study drug
  5. Adequate hepatic function within 14 days before drug administration defined as: or ALT ≤ 1.5 times the values, total within normal limits.

Exclusion criteria

Exclusion Criteria:

  1. History of allergic conditions or allergic diseases, or a history of allergic reactions attributed to drugs. Those who cannot follow a uniform diet for special dietary requirements.
  2. History of seizure,including any febrile seizure, or , or any condition that may pre-dispose to seizure (such as prior stroke, brain arteriovenous malformation, brain trauma with requiring hospitalization, and lacunar cerebral infarction).
  3. Have a malignant tumor or a history of malignant tumor in the 5 years prior to screening (except for patients with non-melanoma skin cancers with no evidence of recurrence, or patients with excised cervical intraepithelial neoplasia).
  4. Subjects with severe infection, trauma, gastrointestinal surgery or other major surgical operations within 4 weeks before screening;
  5. Abnormal blood pressure response, or abnormal blood pressure assessed by the investigator.
  6. Having a history of clinically significant abnormalities (history of tachycardia/bradycardia requiring medical therapy, II-III degree atrioventricular block, or >450ms for males,>460ms for females(corrected by Fridericia's formula), or other clinically significant abnormals assessed by the investigator.
  7. Estimated (eGFR) \<60 mL/min/1.73 m2, according to the modification of diet in renal disease equation.
  8. Those who plan to undergo surgery, or intent to intent to be hospitalized during the trial.
  9. A positive test for antibody at screening.
  10. Received any drugs that inhibit or induce the CYP450 enzyme (i.e., phenytoin, rifampin, carbamazepine, fluvoxamine, enoxacin, ticlopidine, gemfibrozil, clopidogrel, clarithromycin, itraconazole, ketoconazole, ritonavir) 4 weeks prior to screening period.
  11. Received any drugs (including Chinese herbal medicine, vitamins and supplements) within 14 days or 5-half-lives (which is longer) prior to dosing;
  12. Participation in another clinical trial within 3 months before dosing.
  13. Those who have lost blood or donated up to 200 mL within 3 months before dosing, or those who plan to donate blood within 1 month after the end of this study.
  14. Smoking more than 5 cigarettes per day within 3 months prior to screening,or who cannot stop using any tobacco products during the study period.
  15. Average weekly intake of alcohol is more than 14 units alcohol (1 units ≈ 360 mL beer, or 45 mL spirits with 40% content, or 150 mL wine) within the 6 months prior to dosing, or a positive ethanol breath test at screening.
  16. Substance abuse or use of soft drugs (e.g., marijuana) or use of hard drugs (e.g., cocaine, amphetamines, phenylcyclohexidine, etc.); Or screening for positive urine drug abuse (drug) tests.
  17. Habitual or excessive consumption (more than 8 cups, 1cup=250mL) of grapefruit juice, tea, coffee and/or caffeinated beverages.
  18. Subjects who are intolerant to venipuncture or have a history of fainting blood or acupuncture.
  19. Those who have received vaccine within 1 month before screening.
  20. Pregnant or lactating women, or those with positive blood pregnancy tests.
  21. Male or female subjects of childbearing age agreed to take effective and safe during treatment and 3 months after treatment.
  22. Subjects with poor compliance, or not suitable for this study as judged by the investigator.

Participants with Hepatic Impairment Only:

  1. Have received liver transplant at any time in the past.
  2. Patients complicated with drug-induced liver injury.
  3. Other causes of acute liver injury.
  4. Patients with liver failure, or combined with hepatic encephalopathy, hepatocellular carcinoma, and esophageal and gastric variceal bleeding and other complications considered by the investigator as unsuitable for the clinical study.
  5. Any history of clinically serious illness or disease or condition except for primary liver disease that the investigator believes may affect the results of the trial, including but not limited to a history of circulatory, endocrine, nervous, digestive, urinary, or hematological, immune, psychiatric, and metabolic disorders.

Participants with Normal Hepatic Function Only:

  1. Any history of clinically serious illness or disease or condition except for primary liver disease that the investigator believes may affect the results of the trial, including but not limited to a history of circulatory, endocrine, nervous, digestive, urinary, or hematological, immune, psychiatric, and metabolic disorders.
  2. Any history of hepatic impairment, or potential presence of liver function impairment by physical examination and laboratory examination at screening.
  3. Positive result of any indicators of surface antigen, antibody within 1 week prior to screening or at screening.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    Healthy Control

    Each healthy participant will receive a single dose of GP681

    Drug: GP681

  • Experimental
    Mild, Child-Pugh A

    Each participant with Child-Pugh A will receive a single dose of GP681

    Drug: GP681

  • Experimental
    Moderate; Child-Pugh B

    Each participant with Child-Pugh B will receive a single dose of GP681

    Drug: GP681

Interventions

  • DrugGP681

    GP681, tablet, oral

06

What researchers measure

Primary outcomes

  1. Peak plasma concentration (Cmax) of the analyte in plasma after oral administration of GP681

    Time frame: Day 1 to Day12

  2. Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable drug plasma concentration after oral administration of GP681

    Time frame: Day 1 to Day12

  3. Area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity after oral administration of GP681

    Time frame: Day 1 to Day12

Secondary outcomes

  1. Time to Cmax (Tmax) of the analyte in plasma

    Time frame: Day 1 to Day12

  2. Terminal elimination half-life (t1/2) of the analyte in plasma

    Time frame: Day 1 to Day12

  3. Apparent Clearance (CLz/F) of the analyte in plasma

    Time frame: Day 1 to Day12

  4. Apparent volume of distribution (Vz/F) of the analyte in plasma

    Time frame: Day 1 to Day12

  5. Number of participants with drug-related adverse events as assessed by CTCAE v5.0

    Time frame: Day 1 to Day12

07

Study locations

1 site
  • Beijing You'an Hospital, Beijing Medical University
    Beijing, Beijing 100069, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2023 to primary completion in Aug 2023, 3 months.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 4, 2023
First posted
Apr 18, 2023
StartActual
Apr 26, 2023
Primary completionActual
Aug 3, 2023
CompletionActual
Oct 20, 2023
Last update
Nov 15, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 15, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05814926
Responsible party
Sponsor
First posted
Apr 18, 2023
Start date
Apr 26, 2023
Primary completion
Aug 3, 2023
Completion
Oct 20, 2023
Last update
Nov 15, 2023

Study contacts

Haibin Yu
principal investigator · Beijing YouAn Hospital
Bin Xu
principal investigator · Beijing YouAn Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: GP681

Start the discussion